# LTR 154: From Procedures to Judgment - Leading Through QMSR Inspections

Page: https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/ltr-154-from-procedures-to-judgment-leading-through-qmsr-inspections
Text version: https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/ltr-154-from-procedures-to-judgment-leading-through-qmsr-inspections.md
Podcast: [Let's Talk Risk! Podcast](https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844)
Published: 2026-05-08T12:00:00+00:00
Episode link: https://naveenagarwalphd.substack.com/p/ltr-154-from-procedures-to-judgment-leading-through-qmsr-inspections
Audio file: https://api.substack.com/feed/podcast/195659423/4ed6aecafad3a1706ed284753e96cfa0.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/ltr-154-from-procedures-to-judgment-leading-through-qmsr-inspections
Duration seconds: 2331

## Resource

Summary “FDA isn’t just inspecting procedures anymore. They are looking at how risk-based decisions are actually made.” In this episode of the Let’s Talk Risk Podcast , host Naveen Agarwal speaks with Michelle Lott about what early FDA 483 observations under QMSR are already revealing: a clear shift from procedural compliance to evaluating how well companies actually make risk-based decisions across their quality systems. This conversation goes beyond clauses and documentation. It explores how FDA is now looking at system effectiveness, how risk must be integrated across the full product lifecycle, and why leadership teams need to rethink how decisions are made, justified, and communicated under increasing ambiguity. Michelle brings a practical, field-level perspective on what is changing, where companies are most vulnerable, and how QA/RA teams can prepare their organizations for a more dynamic, judgment-driven inspection model. Key Points * FDA is increasingly citing deficiencies in risk management and system-level effectiveness , not just individual subsystems. * QMSR shifts inspections toward how decisions are made , not just whether procedures exist. * ISO 14971 alone is not enough—risk must extend across processes, lifecycle stages, and QMS interactions. * Post-market signals—not just complaints—are becoming critical inputs to risk management. * Leadership involvement, especially through management review , will face greater scrutiny under QMSR. Chapters 00:00 – QMSR and the New FDA Inspection Lens What early 483s reveal about how inspections are changing 05:30 – Risk Management Beyond the Procedure (Clause 7.1) Why risk must connect across the full product lifecycle 10:40 – What “Risk-Based Approach” Really Means (Clause 4.1.2(b)) How FDA may evaluate decision-m…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/ltr-154-from-procedures-to-judgment-leading-through-qmsr-inspections/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/ltr-154-from-procedures-to-judgment-leading-through-qmsr-inspections.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.